MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$1,629,082
Unit: Dollar
Positive Cash Flow Breakdown
Stock-based compensation
Accounts payable
Sale of common stock via atm pro...
Unreimbursed expenses related p...
Negative Cash Flow Breakdown
Net loss
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-3,948,675
-5,657,137
-7,922,733
-4,151,845
Amortization
-
-
0
0
Stock-based compensation
1,484,762
1,544,214
2,170,683
1,544,214
Accounts payable
519,472
-365,461
2,140,193
-187,590
Deferred compensation
-
-
367,538
-
Unreimbursed expenses related party (accrued)
4,695
-224,114
69,662
123,982
Net cash used in operating activities
-1,939,746
-4,702,498
-3,174,657
-2,671,239
Sale of common stock via atm program, net of costs
310,664
9,029,912
5,545,700
3,208,116
Net proceeds from exercise of remaining underwriter warrants
-
-
0
145,000
Net cash provided by financing activities
310,664
9,029,912
5,545,700
3,353,116
Net increase (decrease) in cash
-1,629,082
4,327,414
2,371,043
681,877
Cash, beginning of period
10,505,435
6,178,021
3,806,978
4,091,990
Cash, end of period
8,876,353
10,505,435
6,178,021
3,806,978
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Sale of common stock
via atm program, net...
$310,664
(-89.98%↓ Y/Y)
Net cash provided by
financing activities
$310,664
(-89.98%↓ Y/Y)
Net increase
(decrease) in cash
-$1,629,082
(-68.49%↓ Y/Y)
Canceled cashflow
$310,664
Stock-based compensation
$1,484,762
(-51.92%↓ Y/Y)
Accounts payable
$519,472
(336.75%↑ Y/Y)
Unreimbursed expenses
related party (accrued)
$4,695
(-32.31%↓ Y/Y)
Net cash used in
operating activities
-$1,939,746
(52.31%↑ Y/Y)
Canceled cashflow
$2,008,929
Net loss
-$3,948,675
(45.79%↑ Y/Y)
Buy us a coffee
Greenwich LifeSciences, Inc. (GLSI)
Greenwich LifeSciences, Inc. (GLSI)